Literature DB >> 25514999

Long-term efficacy of donepezil for relapse of visual hallucinations in patients with dementia with Lewy bodies.

Katsuyuki Ukai1,2, Hiroshige Fujishiro2, Shuji Iritani2, Norio Ozaki2.   

Abstract

BACKGROUND: The use of cholinesterase inhibitors is recommended for the treatment of dementia with Lewy bodies (DLB) in the guidelines of the DLB Consortium. However, no consensus regarding therapeutic approaches for DLB-related visual hallucinations has been reached. To the best of our knowledge, an appropriate dose of donepezil for the treatment of DLB at each stage has not been discussed.
METHODS: Eight patients suffering from DLB with visual hallucinations were treated with donepezil. We summarize the effects of donepezil on these visual hallucinations chronologically in all cases and discuss its efficacy and characteristics.
RESULTS: Donepezil contributed to the complete disappearance of visual hallucinations in all cases, and its effects were maintained for more than 6 months. However, relapses of visual hallucinations also occurred in all cases. Against these relapses, an increased dose of donepezil was very effective in resolving them again in almost all cases in this study.
CONCLUSIONS: Donepezil was highly effective against visual hallucinations in DLB patients, but there were some issues regarding pharmacotherapy for DLB.
© 2014 The Authors. Psychogeriatrics © 2014 Japanese Psychogeriatric Society.

Entities:  

Keywords:  appropriate dose; cholinesterase inhibitor; dementia with Lewy bodies (DLB); donepezil; pharmacotherapy; visual hallucinations

Year:  2014        PMID: 25514999     DOI: 10.1111/psyg.12089

Source DB:  PubMed          Journal:  Psychogeriatrics        ISSN: 1346-3500            Impact factor:   2.440


  5 in total

Review 1.  Clinical drug development for dementia with Lewy bodies: past and present.

Authors:  Garam Lee; Jeffrey Cummings; Boris Decourt; James B Leverenz; Marwan N Sabbagh
Journal:  Expert Opin Investig Drugs       Date:  2019-10-28       Impact factor: 6.206

Review 2.  Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.

Authors:  Paul Noufi; Rita Khoury; Sajeeka Jeyakumar; George T Grossberg
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

Review 3.  Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia with Lewy Bodies.

Authors:  Jeffrey Cummings; Te-Jen Lai; Solaphat Hemrungrojn; E Mohandas; Sang Yun Kim; Girish Nair; Amitabh Dash
Journal:  CNS Neurosci Ther       Date:  2016-01-18       Impact factor: 5.243

4.  Acetylcholinesterase inhibitors in treatment-resistant psychotic depression.

Authors:  Chris Smart; Hamish McAllister-Williams; David Andrew Cousins
Journal:  Ther Adv Psychopharmacol       Date:  2017-07-10

Review 5.  Approach to Cognitive Impairment in Parkinson's Disease.

Authors:  Qiang Zhang; Georgina M Aldridge; Nandakumar S Narayanan; Steven W Anderson; Ergun Y Uc
Journal:  Neurotherapeutics       Date:  2020-11-17       Impact factor: 6.088

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.